SecSonar.com

VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

VistaGen Therapeutics, Inc. (VTGN) is a Biotechnology company based in US with a market capitalization of $20.9M. Revenue declined 54.3% year-over-year and free cash flow was negative at -$42.3M. This page tracks VTGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 48 employees · IPO Jun 21, 2011

Valuation

Valuation & price

$0.62 · as of May 17, 2026 · -87.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.59

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.90$2.57$0.25Jul 25Dec 25Jul 26Jul 7, 25$2.21Jul 9, 25$2.49Jul 11, 25$2.38Jul 15, 25$2.25Jul 17, 25$2.54Jul 21, 25$2.55Jul 23, 25$2.73Jul 25, 25$3.08Jul 29, 25$3.06Jul 31, 25$2.87Aug 4, 25$2.91Aug 6, 25$2.97Aug 11, 25$2.84Aug 13, 25$2.93Aug 15, 25$3.31Aug 19, 25$3.17Aug 21, 25$3.06Aug 25, 25$3.03Aug 27, 25$3.18Aug 29, 25$3.34Sep 3, 25$3.69Sep 5, 25$3.55Sep 9, 25$3.61Sep 11, 25$3.50Sep 16, 25$2.91Sep 18, 25$3.04Sep 22, 25$3.33Sep 24, 25$3.47Sep 26, 25$3.53Sep 30, 25$3.55Oct 2, 25$3.60Oct 6, 25$3.89Oct 8, 25$4.02Oct 10, 25$4.03Oct 14, 25$4.01Oct 16, 25$4.05Oct 21, 25$4.23Oct 23, 25$4.16Oct 27, 25$3.90Oct 29, 25$3.96Oct 31, 25$3.94Nov 4, 25$4.07Nov 6, 25$4.02Nov 10, 25$3.98Nov 12, 25$4.07Nov 14, 25$3.80Nov 18, 25$4.63Nov 20, 25$4.45Nov 25, 25$4.69Nov 28, 25$4.90Dec 2, 25$3.60Dec 4, 25$4.28Dec 8, 25$4.29Dec 10, 25$4.53Dec 12, 25$4.25Dec 16, 25$4.36Dec 18, 25$0.74Dec 22, 25$0.75Dec 24, 25$0.73Dec 29, 25$0.66Jan 2, 26$0.68Jan 6, 26$0.72Jan 8, 26$0.70Jan 12, 26$0.70Jan 14, 26$0.70Jan 16, 26$0.66Jan 21, 26$0.63Jan 23, 26$0.65Jan 27, 26$0.61Jan 29, 26$0.54Feb 2, 26$0.58Feb 4, 26$0.53Feb 9, 26$0.56Feb 11, 26$0.57Feb 13, 26$0.51Feb 18, 26$0.52Feb 20, 26$0.56Feb 24, 26$0.56Feb 26, 26$0.60Mar 2, 26$0.60Mar 4, 26$0.60Mar 6, 26$0.61Mar 10, 26$0.61Mar 12, 26$0.63Mar 17, 26$0.65Mar 19, 26$0.64Mar 23, 26$0.62Mar 25, 26$0.61Mar 27, 26$0.57Mar 31, 26$0.57Apr 2, 26$0.59Apr 7, 26$0.54Apr 9, 26$0.56Apr 13, 26$0.58Apr 15, 26$0.61Apr 17, 26$0.63Apr 22, 26$0.60Apr 24, 26$0.59Apr 28, 26$0.60Apr 30, 26$0.61May 4, 26$0.62May 6, 26$0.61May 8, 26$0.61May 12, 26$0.62May 14, 26$0.65May 18, 26$0.60May 20, 26$0.64May 22, 26$0.65May 28, 26$0.63Jun 1, 26$0.65Jun 3, 26$0.56Jun 5, 26$0.54Jun 9, 26$0.54Jun 11, 26$0.57Jun 15, 26$0.57Jun 17, 26$0.69Jun 22, 26$0.64Jun 24, 26$0.66Jun 26, 26$0.70Jul 2, 26$0.25
$0.2352-week range$4.90
Loading valuation history…

Fundamentals

Key fundamentals

$20.9M

Market cap

-54.3%

Revenue growth (YoY)

100.0%

Gross margin

-$42.3M

Free cash flow (USD)

-$79M

Net debt

Net cash position

58.7%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$1.3MFY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$1.1MFY 2022$1.1MFY 2023$-227.0KFY 2024$1.1MFY 2025$486.0K
$0$486K

Free cash flow by year

2016 → 2025

FY 2016$-4.8MFY 2017$-7.5MFY 2018$-9.1MFY 2019$-14.7MFY 2020$-15.8MFY 2021$-12.3MFY 2022$-45.5MFY 2023$-49.9MFY 2024$-25.9MFY 2025$-42.3M
-$4.8M-$42.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: Jun 15, 2026 (EPS $-0.37)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventPhase 3 Trial ResultsJun 30, 2026Filing
  • 8-K eventDirector Not Standing for Re-electionJun 17, 2026Filing
  • 8-K eventFiscal Year 2026 ResultsJun 15, 2026Filing
  • Annual report10-K FiledJun 15, 2026Filing
  • 8-K eventClinical Program UpdateJun 9, 2026Filing
  • 8-K eventIndemnification AgreementMay 19, 2026Filing
  • 8-K eventPositive Study ResultsMay 12, 2026Filing
  • 8-K eventClinical Trial UpdateMay 8, 2026Filing
  • 8-K eventFDA Approval ReceivedApr 28, 2026Filing
  • 8-K eventStock Option GrantsApr 13, 2026Filing

Questions

Frequently asked questions

What is VistaGen Therapeutics, Inc.'s market cap?

VistaGen Therapeutics, Inc. (VTGN) has a market capitalization of $20.9M.

What is VTGN's P/E ratio?

A meaningful P/E ratio is not available for VTGN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is VTGN's price-to-book (P/B) ratio?

VTGN trades at 0.59 times book value per share.

When did VistaGen Therapeutics, Inc. last report earnings?

VTGN last reported earnings on June 15, 2026; the next date is not yet scheduled.

Are insiders buying VTGN stock?

SEC Form 4 filings show no open-market insider buys at VistaGen Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

KZIA

Kazia Therapeutics Limited

$20.8M

PLUR

Pluri Inc.

$20.7M

ABVC

ABVC BioPharma, Inc.

$20.3M

DARE

Daré Bioscience, Inc.

$21.6M

XCUR

Exicure, Inc.

$20.1M

SER

Serina Therapeutics, Inc.

$20M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.